145 related articles for article (PubMed ID: 19192652)
41. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Onda M; Nagata S; Ho M; Bera TK; Hassan R; Alexander RH; Pastan I
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4225-31. PubMed ID: 16857795
[TBL] [Abstract][Full Text] [Related]
42. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
43. Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
Sato T; Suzuki Y; Mori T; Maeda M; Abe M; Hino O; Takahashi K
Cancer Med; 2014 Oct; 3(5):1377-84. PubMed ID: 25045139
[TBL] [Abstract][Full Text] [Related]
44. Mesothelin-family proteins and diagnosis of mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441
[TBL] [Abstract][Full Text] [Related]
45. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Canessa PA; Chella A; Lucchi M; Mussi A; Mutti L
Int J Biol Markers; 2010; 25(3):164-70. PubMed ID: 20878622
[TBL] [Abstract][Full Text] [Related]
46. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
47. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
Di Serio F; Fontana A; Loizzi M; Capotorto G; Maggiolini P; Mera E; Bisceglia L; Molinini R
Clin Chem Lab Med; 2007; 45(5):634-8. PubMed ID: 17484626
[TBL] [Abstract][Full Text] [Related]
48. Soluble mesothelin related protein in mesothelioma.
Creaney J; Christansen H; Lake R; Musk AB; de Klerk N; Robinson BW
J Thorac Oncol; 2006 Feb; 1(2):172-4. PubMed ID: 17409849
[No Abstract] [Full Text] [Related]
49. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs.
Takata A; Yamauchi H; Toya T; Miyamoto-Kohno S; Iwatatsu Y; Teranaka I; Aminaka M; Yamashita K; Kohyama N
Toxicol Appl Pharmacol; 2011 Apr; 252(2):123-9. PubMed ID: 20933535
[TBL] [Abstract][Full Text] [Related]
51. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
Weber DG; Taeger D; Pesch B; Kraus T; Brüning T; Johnen G
Cancer Biomark; 2007; 3(6):287-92. PubMed ID: 18048966
[TBL] [Abstract][Full Text] [Related]
52. Plasma osteopontin is an independent prognostic marker for head and neck cancers.
Petrik D; Lavori PW; Cao H; Zhu Y; Wong P; Christofferson E; Kaplan MJ; Pinto HA; Sutphin P; Koong AC; Giaccia AJ; Le QT
J Clin Oncol; 2006 Nov; 24(33):5291-7. PubMed ID: 17114663
[TBL] [Abstract][Full Text] [Related]
53. Biomarkers for mesothelioma.
Scherpereel A; Lee YC
Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
[TBL] [Abstract][Full Text] [Related]
54. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
[TBL] [Abstract][Full Text] [Related]
55. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.
Hellstrom I; Friedman E; Verch T; Yang Y; Korach J; Jaffar J; Swisher E; Zhang B; Ben-Baruch G; Tan MC; Goedegebuure P; Hellstrom KE
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1520-6. PubMed ID: 18559570
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
57. ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.
Ito T; Kajino K; Abe M; Sato K; Maekawa H; Sakurada M; Orita H; Wada R; Kajiyama Y; Hino O
Oncol Rep; 2014 Jan; 31(1):27-33. PubMed ID: 24146039
[TBL] [Abstract][Full Text] [Related]
58. Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.
Koyanagi AI; Kajino K; Nojiri S; Abe M; Kobayashi T; Sugitani Y; Yue L; Ohtsuji N; Arakawa A; Sato T; Takahashi K; Suzuki K; Orimo A; Yao T; Hino O
Juntendo Iji Zasshi; 2023; 69(2):124-136. PubMed ID: 38854453
[TBL] [Abstract][Full Text] [Related]
59. [Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].
Simonini S; Foddis R; Filiberti R; Puntoni R; Mutti L; Ambrosino N; Chella A; Guglielmi G; Buselli R; Iuzzolini M; Mignani A; Ottenga F; Cristaudo A
G Ital Med Lav Ergon; 2007; 29(3 Suppl):339-42. PubMed ID: 18409715
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
